ZEN Graphene Solutions Ltd (ZTEK) - Total Liabilities

Latest as of September 2025: $5.18 Million USD

Based on the latest financial reports, ZEN Graphene Solutions Ltd (ZTEK) has total liabilities worth $5.18 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ZEN Graphene Solutions Ltd (ZTEK) net asset momentum to track the company's year-over-year net asset growth rate.

ZEN Graphene Solutions Ltd - Total Liabilities Trend (2010–2025)

This chart illustrates how ZEN Graphene Solutions Ltd's total liabilities have evolved over time, based on quarterly financial data. See ZTEK free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

ZEN Graphene Solutions Ltd Competitors by Total Liabilities

The table below lists competitors of ZEN Graphene Solutions Ltd ranked by their total liabilities.

Company Country Total Liabilities
NFC Corporation
KQ:265740
Korea ₩24.88 Billion
KMH Co. Ltd
KQ:122450
Korea ₩450.07 Billion
Teknosa Ic ve Dis Ticaret AS
IS:TKNSA
Turkey TL17.65 Billion
Deutsch Motors Inc
KQ:067990
Korea ₩1.30 Trillion
Abeo SAS
PA:ABEO
France €231.07 Million
Shang Gong Group Co Ltd B
SHG:900924
China $3.51 Billion
Abra Information Technologies Ltd
TA:BBYL
Israel ILA23.47 Million
OnMobile Global Limited
NSE:ONMOBILE
India Rs3.34 Billion

Liability Composition Analysis (2010–2025)

This chart breaks down ZEN Graphene Solutions Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ZEN Graphene Solutions Ltd market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.79 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.44 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.31 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how ZEN Graphene Solutions Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for ZEN Graphene Solutions Ltd (2010–2025)

The table below shows the annual total liabilities of ZEN Graphene Solutions Ltd from 2010 to 2025.

Year Total Liabilities Change
2025-03-31 $3.65 Million +104.82%
2024-03-31 $1.78 Million -38.70%
2023-03-31 $2.90 Million +5.79%
2022-03-31 $2.75 Million -1.52%
2021-03-31 $2.79 Million +428.46%
2020-03-31 $527.58K -18.41%
2019-03-31 $646.64K +325.32%
2018-03-31 $152.03K +82.52%
2017-03-31 $83.30K -8.50%
2016-03-31 $91.04K -49.68%
2015-03-31 $180.92K -33.57%
2014-03-31 $272.33K -45.59%
2013-03-31 $500.56K -51.69%
2012-03-31 $1.04 Million +2.43%
2011-03-31 $1.01 Million +548.91%
2010-03-31 $155.90K --

About ZEN Graphene Solutions Ltd

NASDAQ:ZTEK USA Medical Instruments & Supplies
Market Cap
$72.97 Million
Market Cap Rank
#20350 Global
#4562 in USA
Share Price
$0.68
Change (1 day)
+23.21%
52-Week Range
$0.37 - $1.06
All Time High
$5.70
About

Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coatings under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds. It also… Read more